CN113366014B - 经修饰的gip肽类似物 - Google Patents
经修饰的gip肽类似物Info
- Publication number
- CN113366014B CN113366014B CN201980090373.3A CN201980090373A CN113366014B CN 113366014 B CN113366014 B CN 113366014B CN 201980090373 A CN201980090373 A CN 201980090373A CN 113366014 B CN113366014 B CN 113366014B
- Authority
- CN
- China
- Prior art keywords
- gip
- seq
- amino acid
- glu
- aeeac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202511386362.3A CN121449720A (zh) | 2018-12-03 | 2019-12-03 | 经修饰的gip肽类似物 |
| CN202511386365.7A CN121449721A (zh) | 2018-12-03 | 2019-12-03 | 经修饰的gip肽类似物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18209896 | 2018-12-03 | ||
| EP18209896.2 | 2018-12-03 | ||
| EP19176739 | 2019-05-27 | ||
| EP19176739.1 | 2019-05-27 | ||
| PCT/EP2019/083506 WO2020115048A1 (en) | 2018-12-03 | 2019-12-03 | Modified gip peptide analogues |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202511386365.7A Division CN121449721A (zh) | 2018-12-03 | 2019-12-03 | 经修饰的gip肽类似物 |
| CN202511386362.3A Division CN121449720A (zh) | 2018-12-03 | 2019-12-03 | 经修饰的gip肽类似物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113366014A CN113366014A (zh) | 2021-09-07 |
| CN113366014B true CN113366014B (zh) | 2025-10-21 |
Family
ID=68731999
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980090373.3A Active CN113366014B (zh) | 2018-12-03 | 2019-12-03 | 经修饰的gip肽类似物 |
| CN202511386365.7A Pending CN121449721A (zh) | 2018-12-03 | 2019-12-03 | 经修饰的gip肽类似物 |
| CN202511386362.3A Pending CN121449720A (zh) | 2018-12-03 | 2019-12-03 | 经修饰的gip肽类似物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202511386365.7A Pending CN121449721A (zh) | 2018-12-03 | 2019-12-03 | 经修饰的gip肽类似物 |
| CN202511386362.3A Pending CN121449720A (zh) | 2018-12-03 | 2019-12-03 | 经修饰的gip肽类似物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12187773B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3891174A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7605747B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102906485B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN113366014B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019391300B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021010447A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3121043A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL283385A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021006505A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202105586YA (cg-RX-API-DMAC7.html) |
| WO (2) | WO2020115049A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122520749A (zh) * | 2019-12-03 | 2026-08-07 | 安泰博医药 | 优化的gip肽类似物 |
| WO2022007809A1 (zh) * | 2020-07-06 | 2022-01-13 | 鸿绪生物医药科技(北京)有限公司 | 新型多肽制剂及其治疗用途 |
| AU2021304762B2 (en) * | 2020-07-06 | 2024-05-02 | Vitalixir (Beijing) Co., Ltd | Novel polypeptide and therapeutic use thereof |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| MX2023014740A (es) * | 2021-06-10 | 2024-03-13 | Antag Therapeutics Aps | Tratamiento de la obesidad y trastornos relacionados con la obesidad. |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2023139106A2 (en) | 2022-01-18 | 2023-07-27 | Novo Nordisk A/S | Long-acting gipr antagonists |
| CN117402219B (zh) | 2022-07-13 | 2024-07-30 | 杭州中美华东制药有限公司 | Glp-1/gip双激动剂及其制备方法和用途 |
| CN118255864A (zh) * | 2022-12-26 | 2024-06-28 | 杭州中美华东制药有限公司 | Gip受体激动剂及其用途 |
| CN116120425A (zh) * | 2022-12-27 | 2023-05-16 | 南京赛诺生物技术有限公司 | 一种glp-1/gip受体双重激动剂及其应用 |
| GB202302686D0 (en) * | 2023-02-24 | 2023-04-12 | Imperial College Innovations Ltd | Novel compounds |
| AU2024224775A1 (en) * | 2023-02-24 | 2025-10-09 | Ip2Ipo Innovations Limited | Compounds |
| WO2024209050A1 (en) * | 2023-04-05 | 2024-10-10 | Antag Therapeutics Aps | Gip activity modulators and orthostatic intolerance |
| AR134436A1 (es) * | 2023-11-22 | 2026-01-14 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario |
| WO2025154020A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
| WO2025154021A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
| WO2025176999A2 (en) * | 2024-02-23 | 2025-08-28 | Ip2Ipo Innovations Limited | Novel compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006086769A2 (en) * | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| WO2016034186A1 (en) * | 2014-09-05 | 2016-03-10 | University Of Copenhagen | Gip peptide analogues |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| US5745335A (en) | 1996-06-27 | 1998-04-28 | Gennum Corporation | Multi-layer film capacitor structures and method |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| AU5518798A (en) | 1996-12-03 | 1998-06-29 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
| JP3270761B2 (ja) | 1998-01-30 | 2002-04-02 | ノボ ノルディスク アクティーゼルスカブ | 注射器 |
| AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| DE69918070T2 (de) | 1998-03-13 | 2005-08-25 | Novo Nordisk A/S | Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien |
| DE69926007T2 (de) | 1998-10-07 | 2005-12-29 | Medical College Of Georgia Research Institute, Inc. | Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon |
| EP1137667B1 (en) | 1998-12-07 | 2004-11-17 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Analogues of glp-1 |
| US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
| GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| ATE272650T1 (de) | 1999-03-29 | 2004-08-15 | Uutech Ltd | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
| SI1724284T1 (sl) | 2000-12-07 | 2009-12-31 | Lilly Co Eli | Glp-1 fuzijski proteini |
| ATE347764T1 (de) | 2001-09-21 | 2006-12-15 | Koninkl Philips Electronics Nv | Gibt es kein spezifisches kontrollmodul? benutzen sie eines das weniger spezifisch ist |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| WO2004067548A2 (en) | 2003-01-31 | 2004-08-12 | Theratechnologies Inc. | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| US8263545B2 (en) * | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| AU2007227202B2 (en) | 2006-03-21 | 2013-08-22 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
| CA2732949C (en) | 2008-08-07 | 2016-12-20 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
| KR20130133103A (ko) | 2008-08-07 | 2013-12-05 | 입센 파마 에스.에이.에스 | N-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(gip)의 유사체 |
| CA2733005C (en) | 2008-08-07 | 2016-09-27 | Ipsen Pharma S.A.S. | Truncated analogues of glucose-dependent insulinotropic polypeptide |
| WO2010016936A1 (en) | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide |
| ES2574835T3 (es) | 2008-08-07 | 2016-06-22 | Ipsen Pharma S.A.S. | Análogos del polipéptido insulinotrópico dependiente de glucosa |
| US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
| RU2013133803A (ru) | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| KR102002783B1 (ko) * | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
| ES2602486T3 (es) * | 2012-06-21 | 2017-02-21 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran actividad de receptor de GIP |
| TW201625668A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
| TW201625669A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
| EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
| EP3310376A4 (en) | 2015-06-17 | 2019-01-23 | The California Institute for Biomedical Research | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF |
| US10774127B2 (en) | 2016-10-12 | 2020-09-15 | University Of Copenhagen | Peptide dual agonists of GIPR and GLP2R |
| EP3556399A1 (en) * | 2016-12-19 | 2019-10-23 | Hanmi Pharm. Co., Ltd. | Brain targeting long-acting protein conjugate |
| WO2018124011A1 (ja) | 2016-12-26 | 2018-07-05 | 花王株式会社 | 運動調節機能向上剤 |
| US20190330332A1 (en) | 2016-12-26 | 2019-10-31 | Kao Corporation | Hypothermia Ameliorating Agent |
| EP3569248B1 (en) | 2016-12-26 | 2023-12-06 | Kao Corporation | Gip inhibitors for improving cognitive function |
| US11572399B2 (en) * | 2017-05-31 | 2023-02-07 | University Of Copenhagen | Long-acting GIP peptide analogues |
-
2019
- 2019-12-03 US US17/298,444 patent/US12187773B2/en active Active
- 2019-12-03 EP EP19812789.6A patent/EP3891174A1/en active Pending
- 2019-12-03 MX MX2021006505A patent/MX2021006505A/es unknown
- 2019-12-03 EP EP19812788.8A patent/EP3891173A1/en active Pending
- 2019-12-03 CN CN201980090373.3A patent/CN113366014B/zh active Active
- 2019-12-03 SG SG11202105586YA patent/SG11202105586YA/en unknown
- 2019-12-03 CA CA3121043A patent/CA3121043A1/en active Pending
- 2019-12-03 BR BR112021010447-0A patent/BR112021010447A2/pt unknown
- 2019-12-03 WO PCT/EP2019/083509 patent/WO2020115049A1/en not_active Ceased
- 2019-12-03 WO PCT/EP2019/083506 patent/WO2020115048A1/en not_active Ceased
- 2019-12-03 JP JP2021552785A patent/JP7605747B2/ja active Active
- 2019-12-03 KR KR1020217019677A patent/KR102906485B1/ko active Active
- 2019-12-03 CN CN202511386365.7A patent/CN121449721A/zh active Pending
- 2019-12-03 KR KR1020257043349A patent/KR20260011770A/ko active Pending
- 2019-12-03 AU AU2019391300A patent/AU2019391300B2/en active Active
- 2019-12-03 CN CN202511386362.3A patent/CN121449720A/zh active Pending
- 2019-12-03 US US17/298,512 patent/US12297250B2/en active Active
-
2021
- 2021-05-24 IL IL283385A patent/IL283385A/en unknown
-
2025
- 2025-03-31 US US19/096,393 patent/US20250376499A1/en active Pending
- 2025-09-24 AU AU2025237957A patent/AU2025237957A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006086769A2 (en) * | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| WO2016034186A1 (en) * | 2014-09-05 | 2016-03-10 | University Of Copenhagen | Gip peptide analogues |
Non-Patent Citations (2)
| Title |
|---|
| Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice;V. Pathak等;《Molecular and Cellular Endocrinology》;第401卷;第120-129页 * |
| V. Pathak等.Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice.《Molecular and Cellular Endocrinology》.2015,第401卷第120-129页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021006505A (es) | 2021-10-01 |
| KR102906485B1 (ko) | 2025-12-31 |
| SG11202105586YA (en) | 2021-06-29 |
| JP7605747B2 (ja) | 2024-12-24 |
| AU2025237957A1 (en) | 2025-10-16 |
| EP3891174A1 (en) | 2021-10-13 |
| KR20260011770A (ko) | 2026-01-23 |
| US20250376499A1 (en) | 2025-12-11 |
| US12297250B2 (en) | 2025-05-13 |
| US20220025010A1 (en) | 2022-01-27 |
| IL283385A (en) | 2021-07-29 |
| CA3121043A1 (en) | 2020-06-11 |
| WO2020115048A1 (en) | 2020-06-11 |
| AU2019391300B2 (en) | 2025-06-26 |
| CN121449721A (zh) | 2026-02-03 |
| CN113366014A (zh) | 2021-09-07 |
| AU2019391300A1 (en) | 2021-07-01 |
| EP3891173A1 (en) | 2021-10-13 |
| US20220298218A1 (en) | 2022-09-22 |
| JP2022509568A (ja) | 2022-01-20 |
| US12187773B2 (en) | 2025-01-07 |
| CN121449720A (zh) | 2026-02-03 |
| WO2020115049A1 (en) | 2020-06-11 |
| BR112021010447A2 (pt) | 2021-08-24 |
| KR20210102911A (ko) | 2021-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250376499A1 (en) | Modified gip peptide analogues | |
| CN110691788B (zh) | 长效gip肽类似物 | |
| CN114761420B (zh) | 优化的gip肽类似物 | |
| CN108135981A (zh) | 胰高血糖素受体激动剂 | |
| KR20150003910A (ko) | Gip-glp-1 이원 작용제 화합물 및 방법 | |
| RU2817673C2 (ru) | Модифицированные аналоги GIP пептида | |
| RU2858286C2 (ru) | Оптимизированные пептидные аналоги gip | |
| CA3064510C (en) | Long-acting gip peptide analogues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |